Crossmark

Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment

Crossref DOI link: https://doi.org/10.1038/s41467-022-32307-y

Published Online: 2022-08-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jensen, Simon Birk Kjær

Janus, Charlotte

Lundgren, Julie Rehné

Juhl, Christian Rimer

Sandsdal, Rasmus Michael https://orcid.org/0000-0003-0590-6285
Olsen, Lisa Møller

Andresen, Anne

Borg, Signe Amalie https://orcid.org/0000-0002-6455-178X
Jacobsen, Ida Christine https://orcid.org/0000-0003-0653-4364
Finlayson, Graham

Stallknecht, Bente Merete

Holst, Jens Juul https://orcid.org/0000-0001-6853-3805
Madsbad, Sten https://orcid.org/0000-0002-5017-1815
Torekov, Signe Sørensen https://orcid.org/0000-0001-6779-0252
License Information

Text and Data Mining valid from 2022-08-15

Version of Record valid from 2022-08-15
More Information

Article History

Received: 5 January 2022

Accepted: 26 July 2022

First Online: 15 August 2022

Competing interests

: SM: Advisory boards: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. Lecture fees: AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. Research Grant Recipient: Novo Nordisk, Boehringer-Ingelheim. JJH: Advisory boards: Novo Nordisk. SST: Research Grant Recipient Novo Nordisk. RMS: Family member holds Novo Nordisk stock. All other authors declare no competing interests.

Document is current

Any future updates will be listed below